QPPV.COM KNOWLEDGE ASSESSMENT

Trastuzumab and Hyaluronidase Subcutaneous Formulation: Administration, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Trastuzumab and Hyaluronidase Subcutaneous Formulation: Administration, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A report states that only part of the subcutaneous injection was administered because the device or procedure was interrupted. Which additional information is most important?

Whether the patient preferred intravenous treatment The amount administered, amount remaining, reason for interruption and any corrective action Only the patient's height The brand name of an unrelated concomitant medicine

Question 2 of 10 Which statement best describes cardiac pharmacovigilance for subcutaneous trastuzumab?

The subcutaneous route removes the need for cardiac assessment Cardiac assessment should use the same biological reasoning as for intravenous trastuzumab, including LVEF and relevant history Only local injection findings are relevant because systemic exposure is avoided Cardiac events should be attributed to hyaluronidase unless proven otherwise

Question 3 of 10 Which medication-error risk is particularly relevant when intravenous and subcutaneous trastuzumab presentations are available in the same healthcare setting?

Confusing a fixed-dose subcutaneous presentation with a weight-based intravenous presentation Assuming that all trastuzumab products contain different active antibodies Using cardiac monitoring to assess an injection-site reaction Recording a batch number for a biologic medicine

Question 4 of 10 An inspector asks whether the pharmacovigilance system can distinguish a wrong route from a wrong product and a wrong dose. Which capability is most relevant?

A coding and data model that captures product presentation, intended and administered route, and dose information A system that records only the seriousness criterion A system that merges all trastuzumab exposures under one product name A system that records only the patient's treatment response

Question 5 of 10 Which control would most directly reduce the risk that route-specific cases are misclassified in a safety database?

Make route a mandatory case-assessment field when multiple presentations exist Store only the active substance and omit formulation details Use one generic administration-reaction category for all routes Remove batch information from the minimum data set

Question 6 of 10 Why is recording only the active substance as 'trastuzumab' inadequate for many pharmacovigilance assessments?

The active substance has different HER2 targets in different formulations The active substance name does not identify the presentation, route, dose model or administration pathway Trastuzumab cannot be assessed unless the patient's diagnosis is known The active substance name is relevant only for product quality investigations

Question 7 of 10 A patient develops painful erythema and swelling at the abdominal injection site after switching from intravenous to subcutaneous trastuzumab. Which initial interpretation is most appropriate?

The event should automatically be classified as an intravenous infusion reaction The event is consistent with a route-specific local injection-site reaction, subject to clinical assessment The event proves that the trastuzumab molecule has changed The event should be excluded from pharmacovigilance because local reactions are expected

Question 8 of 10 How should pregnancy exposure to the subcutaneous formulation generally be approached in pharmacovigilance?

As unrelated to trastuzumab because hyaluronidase is included Within the established trastuzumab embryo-fetal risk framework, while documenting the route As a route-specific risk that can be assessed without considering trastuzumab exposure As irrelevant unless an injection-site reaction also occurred

Question 9 of 10 Which patient information would be most useful when evaluating a possible trastuzumab-associated cardiac event?

Injection-site dimensions only Baseline cardiac status, prior or concomitant anthracycline use, serial LVEF and clinical symptoms The colour of the administration room Whether the patient previously received an oral medicine

Question 10 of 10 Which information is most important for distinguishing a local injection-site reaction from a systemic administration-related reaction?

The patient's nationality and prescriber specialty The timing, symptoms, anatomical site and route of administration The brand colour and carton design only The patient's previous unrelated vaccinations

Trastuzumab and Hyaluronidase Subcutaneous Formulation: Administration, Safety and Pharmacovigilance

Cookie Settings